28583-62-2

Usage

Uses

Used in Pharmaceutical Research and Development:
N1-(4-BUTYRYL-3-HYDROXYPHENYL)ACETAMIDE is used as a pharmaceutical candidate for its potential therapeutic effects on pain and inflammation. Its analgesic and anti-inflammatory properties make it a valuable asset in the development of new treatments for various conditions characterized by pain and inflammation.
Used in Pain Management:
N1-(4-BUTYRYL-3-HYDROXYPHENYL)ACETAMIDE is used as a pain reliever for its ability to alleviate pain associated with various conditions. Its analgesic properties make it a potential alternative to conventional pain management therapies.
Used in Anti-Inflammatory Treatments:
N1-(4-BUTYRYL-3-HYDROXYPHENYL)ACETAMIDE is used as an anti-inflammatory agent for its capacity to reduce inflammation in various medical conditions. Its anti-inflammatory properties can contribute to the development of new treatments for inflammatory disorders.
Used in Drug Discovery:
N1-(4-BUTYRYL-3-HYDROXYPHENYL)ACETAMIDE is used as a starting point for drug discovery, as its biological activity and potential therapeutic effects make it a valuable compound for further research and development in the pharmaceutical industry.

InChI:InChI=1/C12H15NO3/c1-3-4-11(15)10-6-5-9(7-12(10)16)13-8(2)14/h5-7,16H,3-4H2,1-2H3,(H,13,14)

Upstream product

• 215949-61-4 3-acetamidophenyl butyrate 
• 141-75-3 butyryl chloride 
• 588-16-9 m-methoxyacetanilide 
• 621-42-1 meta-hydroxyacetanilide 

Downstream Products

• 28584-05-6 N-(4-Butyryl-3-cyclopropylmethoxy-phenyl)-acetamide 
• 1434686-56-2 C₂₃H₂₆INO₃ 
• 1349821-00-6 6-butyl-3-(3,5-dimethylisoxazol-4-yl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one 
• 1349820-99-0 6-butyl-3-(4-chloro-2-methylphenyl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one 
• 1349820-97-8 6-butyl-3-(2-fluoro-4-(trifluoromethyl)phenyl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one 
• 1349820-93-4 6-butyl-3-(2,4-dimethylphenyl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one 
• 1349820-87-6 6-butyl-2-methyl-3-(2-methyl-4-(4-(trifluoromethoxy)phenoxy)phenyl)-7-(2-phenoxyethoxy)quinolin-4(1H)-one 
• 19828-71-8 4-butyl-3-(2-phenoxyethoxy)aniline 
• 22932-83-8 N-(3-hydroxy-4-(1-hydroxybutyl)phenyl)acetamide 
• 1349820-44-5 6-butyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one 
• 1349820-40-1 N-(4-butyl-3-(2-phenoxyethoxy)phenyl)acetamide 
• 1349820-89-8 6-butyl-2-methyl-3-(2-methyl-4-(trifluoromethyl)phenyl)-7-(2-phenoxyethoxy)quinolin-4(1H)-one 
• 1349820-84-3 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(4-((4-(trifluoromethoxy)phenoxy)methyl)phenyl)quinolin-4(1H)-one 
• 1349820-83-2 6-butyl-3-(3-(4-fluorophenoxy)phenyl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one 

Relevant academic research and scientific papers

4(1H)-Quinolones Having Antimalarial Activity With Reduced Chemical Resistance

Provided are 4(1H)-quinolone derivatives effective in inhibiting or eliminating the viability of at least one of the stages in the life-cycle of the malarial parasite, and to show a reduced propensity to induce resistance to the compound by the target parasite. In particular, the compounds can be derivatives of phenoxyethoxy-quinolones, and including, but not only, 7-(2-phenoxyethoxy)quinolin derivatives. These compounds may be administered by themselves, with at least one other derivative compound, or with other antimalarial compounds, to an animal or human subject. The therapeutic compositions can be and formulated to reduce the extent of a Plasmodium infection in the recipient subject, or to reduce the likelihood of the onset or establishment of a Plasmodium infection if administered prior to the parasite contacting the subject. The therapeutic compositions can be formulated to provide an effective single dose amount of an antimalarial compound or multiple doses for administering over a period of time.

Synthesis, antimalarial activity, and structure-activity relationship of 7-(2-Phenoxyethoxy)-4(1H)-quinolones

ICI 56,780 (5) displayed causal prophylactic and blood schizonticidal activity (ED50 = 0.05 mg/kg) in rodent malaria models but produced rapid acquisition of parasitological resistance in P. berghei infected mice. Herein we describe the synthesis of analogues of 5 with EC50 as low as 0.15 nM against multidrug resistant P. falciparum. Optimal activity with low cross-resistance indexes (RI) to atovaquone was achieved by introducing ortho-substituted aryl moieties at the 3-position of the 7-(2-phenoxyethoxy)- 4(1H)-quinolone core. (Figure presented

Antitumor effects of guanosine-analog phosphonates identified by molecular modelling

Aiming to address new drug targets, molecular modelling is gaining increasing importance although the prediction capability of the in silico method is still under debate. For an improved treatment of actinic keratosis and squamous cell carcinoma, inhibitors of human DNA polymerase α (pol α) are developed by docking nucleoside phosphonate diphosphates into the active site of pol α. The most promising prodrugs OxBu and OxHex were then prepared by total synthesis and tested in the squamous cancer cell line SCC25. OxBu and OxHex proved cytotoxic and antiproliferative in the nanomolar concentration range and thus exceeded activity of aphidicolin, the relevant model compound, and 5-fluorouracil, the current standard for the therapy of actinic keratosis. Interestingly, the cytotoxicity in normal human keratinocytes with OxHex was clearly less pronounced and even not detectable with OxBu. Moreover, cytotoxicity of OxBu in particular with the colorectal carcinoma cell line HT29 even surmounted cytotoxicity in SCC25, and other tumor cell lines were influenced, too, by both agents. Taken together, OxBu and OxHex may offer a new approach to cancer therapy, given the agents are sufficiently well tolerated in vivo which is to be suspected beside their chemical structure.